Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Iron-deficiency anemia (IDA) accounts for majority of anemia. Although iron replacement therapy is effective, in Japan, conventional iron formulations have disadvantages such as gastrointestinal side effects for oral formulations and issues of frequent administration for intravenous (IV) formulations. Ferric carboxymaltose (FCM), which overcomes these limitations, is widely used as an IV iron source overseas. In this multi-center, open-label, single-arm study, we investigated the safety and efficacy of FCM up to 12 weeks after the start of administration in patients with IDA caused by digestive diseases. Thirty-nine patients diagnosed with IDA based on hemoglobin and serum ferritin levels were included. Eligible subjects were administered FCM until the total calculated iron dose (1000 or 1500 mg) was achieved over intervals of at least 1 week. A single iron dose was 500 mg. In the full analysis set (n = 39), the incidence of adverse events and adverse drug reactions was 71.8 and 48.7%, respectively. All events were as expected from the safety profile of IV iron. The mean change from baseline (10.39 g/dL) to the highest observed hemoglobin level was 3.31 g/dL. These results indicate the safety and efficacy of FCM for treating IDA caused by digestive diseases in Japanese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. World Health Organization. Iron deficiency anemia-assessment, prevention, and control. A guide for program managers. 2001. Report No.: Document WHO/NHD/01.3.

  2. Harigae H. Iron metabolism and related diseases: an overview. Int J Hematol. 2018;107:5–6.

    Article  CAS  PubMed  Google Scholar 

  3. Adamson JW. Iron deficiency and other hypoproliferative anemias. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill Companies; 2013. pp. 844–51.

    Google Scholar 

  4. Cada DJ, Levien TL, Baker DE. Ferric carboxymaltose. Hosp Pharm. 2014;49:52–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ikuta K, Shimura A, Terauchi M, Yoshii K, Kawabata Y. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia. Int J Hematol. 2018;107:519–27.

    Article  CAS  PubMed  Google Scholar 

  6. Ikuta K, Hanashi H, Hirai K, Ota Y, Matsuyama Y, Shimura A, Terauchi M, Momoeda M. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2018. https://doi.org/10.1007/s12185-018-2501-8.

    Article  PubMed  Google Scholar 

  7. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182–92.

    Article  CAS  PubMed  Google Scholar 

  8. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846–53.

    Article  CAS  Google Scholar 

  9. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16–30.

    Article  CAS  Google Scholar 

  10. Suzuki T, Ozawa K. Post-transfusion iron overload. J Jpn Soci Intern Medi. 2012;101:1986–93. (in Japanese).

    Article  CAS  Google Scholar 

  11. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the patients and their families for their contributions.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, 078-8510, Japan

    Katsuya Ikuta

  2. Kinshukai Infusion Clinic, Osaka, Japan

    Hiroaki Ito

  3. Matsushima Clinic Shiodome, Tokyo, Japan

    Keiji Takahashi

  4. Clinical Research 2, Zeria Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan

    Shinya Masaki & Masaru Terauchi

  5. IBD Center, Toho University Sakura Medical Center, Sakura, Japan

    Yasuo Suzuki

Authors
  1. Katsuya Ikuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keiji Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinya Masaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaru Terauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuo Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katsuya Ikuta.

Ethics declarations

Conflict of interest

The present study was performed as a Phase III study funded by Zeria Pharmaceutical Co., Ltd. Ito, Takahashi, and Suzuki received research funding from Zeria Pharmaceutical Co., Ltd. Ikuta received personal fees as a medical specialist from Zeria Pharmaceutical Co., Ltd. Masaki and Terauchi are employees of Zeria Pharmaceutical Co., Ltd.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikuta, K., Ito, H., Takahashi, K. et al. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study. Int J Hematol 109, 50–58 (2019). https://doi.org/10.1007/s12185-018-2529-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-018-2529-9

Keywords

Search

Navigation